Development of a New Immunochemistry Method Using Antibodies of Proteins Related Pancreatic Cancer

BACKGROUND / AIMS: The sensitivity of endoscopic ultrasound-guided aspiration cytology used to distinguish the pancreatic mass is low and clinical usefulness is not secured. The aim of this study was to evaluate clinical efficacy of a new differential staining method for cytology which is difficult to differentiate by the conventional staining method using pancreatic cancer related protein expressed only in pancreatic cancer.

Hypothesis: The statistical significance between conventional staining method and MARS1 staining in the pancreatic cancer cells collected by endoscopic ultrasound-guided aspiration will be compared to prove the usefulness of the new staining method.

Clinical study design: The expression of MARS1 in the pancreatic cancer cell line obtained by endoscopic ultrasound in patients suspected of having pancreatic cancer using Immunofluorescence or immunohistochemistry staining will be performed to differentiate the presence of the tumor. The sensitivity and specificity of the new staining method will be compared with the conventional staining method and its usefulness be confirmed.

Inclusion criteria

• Patients with pancreatic cancer confirmed by imaging (CT, MRI, PET-CT)
• Patients with pancreatic cancer diagnosed using cytology by endoscopic ultrasound
• Patients who underwent surgical treatment with pancreatic cancer

Exclusion criteria

• Minors under the age of 19, vulnerable subjects such as illiteracy
• Excludes necrotic specimens
• Samples with non-diagnostic cytology results and insufficient cells for further evaluation
• Samples classified as neoplastic (benign or other)